Seres Therapeutics (MCRB) Non-Current Assets (2014 - 2026)

Seres Therapeutics has disclosed Non-Current Assets across 13 years of filings, most recently posting $59.2 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 37.72% year-over-year to $59.2 million; the TTM figure through Jun 2026 stood at $325.8 million (down 18.59% YoY), while the FY2025 annual figure was $88.8 million, down 12.18% from the prior year.
• Non-Current Assets came in at $59.2 million for Q2 2026 at Seres Therapeutics, down from $85.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $183.2 million in Q4 2023 to a low of $56.6 million in Q1 2022.
• Average Non-Current Assets over 5 years is $114.4 million, with a median of $99.6 million recorded in 2024.
• Year-over-year, Non-Current Assets surged 200.64% in 2022 and tumbled 44.85% in 2025.
• Over 5 years, Non-Current Assets stood at $154.0 million in 2022, then increased by 18.94% to $183.2 million in 2023, then slumped by 44.79% to $101.1 million in 2024, then retreated by 12.18% to $88.8 million in 2025, then plunged by 33.3% to $59.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $59.2 million in Q2 2026, $85.8 million in Q1 2026, and $88.8 million in Q4 2025.